Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.
2L+ high-risk follicular lymphoma
1L high-risk large B-cell lymphoma
2L large B-cell lymphoma outpatient
Pediatric acute lymphocytic leukemia
Basket (rare B-cell malignancies)
Relapsed/refractory multiple myeloma
Relapsed/refractory acute myeloid leukemia
3L+ diffuse large B-cell lymphoma
1Global strategic collaboration to co-develop and co-commercialize with Arcellx.
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.
Some of the content on this page is not intended for users outside the US.